Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
35.00
-0.33 (-0.93%)
At close: Dec 5, 2025, 4:00 PM EST
35.05
+0.05 (0.14%)
After-hours: Dec 5, 2025, 5:01 PM EST
Travere Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Travere Therapeutics stock have an average target of 37.21, with a low estimate of 25 and a high estimate of 47. The average target predicts an increase of 6.31% from the current stock price of 35.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Travere Therapeutics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 7 | 7 |
| Buy | 8 | 8 | 8 | 8 | 7 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +34.29% | Nov 28, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $26 → $35 | Hold | Maintains | $26 → $35 | n/a | Nov 4, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $30 → $40 | Strong Buy | Maintains | $30 → $40 | +14.29% | Oct 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +34.29% | Sep 19, 2025 |
| Stifel | Stifel | Hold Maintains $20 → $25 | Hold | Maintains | $20 → $25 | -28.57% | Sep 12, 2025 |
Financial Forecast
Revenue This Year
513.82M
from 233.18M
Increased by 120.36%
Revenue Next Year
705.64M
from 513.82M
Increased by 37.33%
EPS This Year
-0.50
from -4.08
EPS Next Year
0.68
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 572.3M | 842.9M | ||||
| Avg | 513.8M | 705.6M | ||||
| Low | 473.7M | 568.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 145.4% | 64.1% | ||||
| Avg | 120.4% | 37.3% | ||||
| Low | 103.2% | 10.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.05 | 2.45 | ||||
| Avg | -0.50 | 0.68 | ||||
| Low | -1.04 | -0.40 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.